Istituto di Ematologia ed Oncologia Medica Seragnoli, Università di Bologna, Bologna, Italy.
Am J Hematol. 2013 Mar;88(3):185-92. doi: 10.1002/ajh.23372. Epub 2013 Jan 22.
By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage III-IV disease and/or high tumor burden. Maintenance rituximab was also recommended in responding patients. In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross-resistant regimens followed by rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy.
采用 GRADE 系统，我们更新了 2006 年来自 SIE、SIES 和 GITMO 小组发布的滤泡细胞淋巴瘤管理指南。我们确认了对 III-IV 期疾病和/或高肿瘤负担患者进行一线化疗免疫治疗的推荐。在有反应的患者中也推荐使用维持性利妥昔单抗。对于在前线治疗后 12 个月以上复发的患者，我们建议使用非交叉耐药方案进行化疗免疫治疗，然后进行利妥昔单抗维持治疗。对于在挽救性化疗免疫治疗后获得缓解的年轻、身体状况良好的患者，我们建议采用大剂量化疗联合造血干细胞移植。
